Pal-GHK

Dosing from the Literature

Published for skin: a cream with 3% Matrixyl 3000 (about 3 ppm Pal-GHK), morning and night for two months, in its maker's own test (Sederma's Matrixyl 3000 dossier), and creams with 3–4 ppm Pal-GHK alone for four weeks, also in the maker's tests (Lintner & Peschard, 2000; Johnson et al., 2018). Not published: an independent trial of Pal-GHK or of Matrixyl 3000 on its own.

Pal-GHK is a topical-only cosmetic ingredient. It is not injected, not taken orally, not reconstituted in bacteriostatic water, and not compounded in peptide compounding pharmacies for systemic use. Dosing is formulation-level (concentration of the active in the finished product), not dose-level (milligrams per kilogram).

What It Is

Pal-GHK (International Nomenclature of Cosmetic Ingredients name "Palmitoyl Tripeptide-1") is a synthetic lipopeptide in which a palmitic acid residue (16-carbon saturated fatty acid) is covalently linked to the N-terminal amino group of the human tripeptide (a chain of 3 amino acids) Gly-His-Lys (GHK) (CosIng; Johnson et al., 2018). The molecule has a molecular weight of about 578.8 Da and is a white powder (Johnson et al., 2018); in Matrixyl 3000 it is dissolved, with Pal-GQPR, in a solution of glycerin, butylene glycol, water, carbomer and polysorbate-20 (Sederma's Matrixyl 3000 dossier).

The parent tripeptide GHK was first isolated from human plasma by Loren Pickart in 1973 as a factor that caused older human liver tissue to synthesize proteins more characteristic of younger tissue. GHK has an extraordinarily high affinity for copper(II), forming the naturally occurring complex GHK-Cu that is present in human plasma, saliva, and urine and declines with age — a compound now widely used as the injectable/topical peptide GHK-Cu (a separate profile on this site). The palmitoylated form, Pal-GHK, was developed by Sederma (a subsidiary of Croda International, France) as a cosmetic-grade derivative of GHK designed specifically for topical penetration, stability on the skin surface, and formulation compatibility with the lipid-rich stratum corneum.

The defining commercial context for Pal-GHK is Matrixyl 3000 — Sederma's flagship anti-aging active, launched in the early-2000s as a successor to Matrixyl (Palmitoyl Pentapeptide-4 / Pal-KTTKS). Matrixyl 3000 pairs Pal-GHK (Palmitoyl Tripeptide-1), at 100 ppm, with Palmitoyl Tetrapeptide-7 (Pal-GQPR / Pal-Gly-Gln-Pro-Arg), at 50 ppm, the latter a tetrapeptide (a chain of 4 amino acids) derived from the immunoglobulin IgG sequence with reported anti-inflammatory effects (Sederma's Matrixyl 3000 dossier). The two peptides are combined in a glycerin/water/butylene-glycol carrier gel and sold to cosmetic formulators as a raw material. Sederma's literature lists use levels of 3–8% of the final formulation, which gives about 3–8 ppm Pal-GHK in the finished product.

Pal-GHK occupies a specific niche in the cosmetic peptide landscape: it is not a novel structure so much as a delivery-engineered version of an endogenous molecule. The "signal" — the GHK head group — is identical to the GHK that the body already produces and that GHK-Cu delivers systemically. The "vehicle" — the palmitoyl chain — is a lipidation strategy borrowed from Sederma's earlier Matrixyl (Pal-KTTKS) to solve the problem of topical delivery: unmodified GHK is hydrophilic and does not partition efficiently into the lipid-rich stratum corneum. Palmitoylation increases lipophilicity enough to allow penetration while preserving the biologically active GHK head group that engages fibroblast (a cell that builds collagen) signaling once it reaches the viable epidermis and dermis. The trade-off is that Pal-GHK is supplied as the free (non-copper-chelated) ligand rather than as the pre-formed GHK-Cu complex, and any copper-dependent activity depends on the peptide acquiring copper from endogenous skin reserves (serum copper, ceruloplasmin, metallothionein, or cosmetic co-ingredients) after penetration.

Mechanism of Action

Sederma, its maker, designed Pal-GHK so that the palmitoyl chain carries the GHK peptide into the skin, where GHK is meant to act as a matrix-repair signal (Lintner & Peschard, 2000; Sederma's Matrixyl 3000 dossier). Most of the mechanism studies cited on this page used GHK or GHK-Cu, not Pal-GHK; the Pal-GHK data come from its maker's cell and skin tests (Lintner & Peschard, 2000; Sederma's Matrixyl 3000 dossier).

• Palmitoylation-driven stratum corneum permeation — The 16-carbon palmitic acid tail, joined to GHK's N-terminus, turns the water-soluble peptide into a lipopeptide with an estimated logP of 4.81 (Johnson et al., 2018). The palmitoyl chain partitions into intercellular lipid lamellae of the stratum corneum, enabling the peptide to traverse the primary permeability barrier. This lipidation strategy was first validated for cosmetic matrikines in Matrixyl (Pal-KTTKS), and the same rationale is applied to Pal-GHK. Unmodified GHK has limited topical permeation; palmitoylation is what makes topical delivery pharmacologically plausible (Lintner and Peschard, Int J Cosmet Sci 2000; Robinson et al. 2005 for the Pal-KTTKS precedent).
• Matrikine (a signaling fragment from broken-down skin matrix) signaling at the fibroblast — The GHK sequence (Gly-His-Lys) occurs in the α2 chain of type I collagen, and the group that first showed its effect on collagen proposed that proteases release it at wounds (Maquart et al., 1988), which would make it a matrikine: a peptide freed by partial breakdown of the extracellular matrix that regulates cells (Maquart et al., 2004). Matrikines bind cell-surface receptors belonging to the cytokine, chemokine, and growth-factor receptor families and signal cells to initiate repair programs (Maquart et al. 2004; Ricard-Blum and Salza, Exp Dermatol 2014, PMID 24815015). In its maker's first fibroblast tests, Pal-GHK itself raised collagen synthesis (Lintner & Peschard, 2000; Johnson et al., 2018); in a later test at 1–7.5 ppm it did not (Sederma's Matrixyl 3000 dossier).
• Collagen synthesis — In the foundational fibroblast-culture study, GHK-Cu stimulated collagen synthesis starting between 10⁻¹² and 10⁻¹¹ M, with a maximum at 10⁻⁹ M, that is 1 nM (Maquart et al., FEBS Lett 1988, PMID 3169264).
• Decorin and glycosaminoglycan synthesis — Beyond collagen, GHK-Cu stimulated fibroblast production of dermatan sulfate, chondroitin sulfate and decorin (a small leucine-rich proteoglycan that regulates collagen fibrillogenesis) (Pickart et al., 2015; PMID 26236730). Pal-GHK alone raised glycosaminoglycan synthesis by up to 46% in its maker's fibroblast test, and changed fibronectin output by −2% to +11% in a later one (Sederma's Matrixyl 3000 dossier). The aggregate effect is an ECM-remodeling program rather than stimulation of a single protein (Pickart 2008, PMID 18644225; Pickart, Vasquez-Soltero, Margolina, BioMed Res Int 2015, PMID 26236730).
• Endogenous copper coordination — the GHK-Cu formation hypothesis — Pal-GHK as supplied is the free ligand (peptide without copper) (CosIng). Plain GHK binds copper(II) about as tightly as the copper-transport site on albumin and forms GHK-Cu (Pickart, 2008; PMID 18644225), so Pal-GHK might pick up copper once in the skin; no study on this page tests whether it does, or whether the palmitoyl chain changes copper binding.
• TGF-β pathway engagement — In lung fibroblasts from people with chronic obstructive pulmonary disease, GHK reversed gene-expression changes linked to low activity of the transforming growth factor beta (TGF-β) pathway (Pickart et al., 2015; PMID 26236730).
• Anti-inflammatory cytokine modulation — GHK and GHK-Cu dampen TNF-α-driven IL-6 (a pro-inflammatory cytokine tied to chronic inflammation) secretion in normal human dermal fibroblasts (Gruchlik et al., Acta Pol Pharm 2012, PMID 23285694).
• Antioxidant / anti-glycation signaling — GHK-Cu has documented activity as a modulator of oxidative stress and a suppressor of lipid peroxidation (Pickart, Vasquez-Soltero, Margolina, Oxid Med Cell Longev 2012, PMID 22666519). No study on this page measures antioxidant activity of Pal-GHK itself.
• Gene-expression reprogramming (Connectivity Map analyses) — Large-scale transcriptomic analyses of GHK/GHK-Cu using the Broad Institute Connectivity Map identified gene-expression changes in the hundreds for the programmes searched — for instance 408 genes up and 230 down in a neuron gene-ontology search, and a reversal of the 127-gene signature of chronic obstructive pulmonary disease — spanning extracellular-matrix synthesis, DNA repair, apoptosis (programmed cell death) regulation and antioxidant enzymes (Pickart and Margolina, Int J Mol Sci 2018, PMID 29986520). These findings are reported for GHK/GHK-Cu. For Pal-GHK, the only gene data are its maker's test on a bank of 450 genes, in which it activated genes for keratinocyte anchoring and differentiation and for matrix components such as syndecan (Sederma's Matrixyl 3000 dossier; Johnson et al., 2018).

What the Research Shows

The research base for Pal-GHK has two problems. Most of the human data come from tests of Matrixyl 3000, which mixes Pal-GHK with Pal-GQPR, so the effect of either cannot be isolated (Sederma's Matrixyl 3000 dossier); and the human tests, including those of Pal-GHK alone, were run by its maker, Sederma, and have not been repeated by an independent group (Lintner & Peschard, 2000).

• Foundational matrikine precedent — Pal-KTTKS (Robinson 2005) — The landmark proof-of-concept for palmitoylated matrikine cosmetics is the Robinson et al. (International Journal of Cosmetic Science 2005; 27(3):155-160) 12-week double-blind split-face placebo-controlled trial in 93 Caucasian women aged 35–55 with photoaged facial skin. This trial studied Pal-KTTKS (Palmitoyl Pentapeptide-4, the active in the original Matrixyl — not Pal-GHK), but established that palmitoyl-peptide matrikines applied topically at parts-per-million concentrations can produce statistically significant reductions in fine lines and wrinkles by both quantitative image analysis and expert-grader assessment. Pal-GHK's development rationale extends this precedent to a different matrikine head group.
• Osborne 2005 pal-KTTKS supporting data — Osborne et al. (J Am Acad Dermatol 2005) reported an 8-week double-blind split-face study of Pal-KTTKS-containing moisturizer in women aged 35–65, corroborating Robinson's findings on fine-line and wrinkle appearance. Again, this is the Matrixyl precursor — not Pal-GHK — but establishes the topical-matrikine performance envelope.
• Matrixyl 3000 manufacturer data (Sederma technical dossier) — Sederma's internal clinical study of Matrixyl 3000 (the Pal-GHK + Pal-GQPR combination) reports reductions of 15–45% in wrinkle depth, volume and density and in the area of deep wrinkles after 56 days of twice-daily application of a cream with 3% Matrixyl 3000 (Sederma's Matrixyl 3000 dossier). These results are reported in trade press, ingredient-supplier technical dossiers, and derivative marketing materials; they have not been published as independent peer-reviewed clinical trials in high-impact dermatology journals.
• Mas-Chamberlin / Lintner 2002 conference data — Mas-Chamberlin, Lintner, Basset et al. (Ann Dermatol Venereol 2002, 20th World Congress of Dermatology conference proceedings) reported a 4-month clinical double-blind study of a palmitoyl-peptide-containing antiwrinkle treatment versus excipient control, forming part of the early clinical dataset underlying Sederma's Matrixyl family of actives.
• GHK-Cu clinical data as mechanistic support — Cosmetic studies of GHK-Cu-containing creams (separate from Pal-GHK) report improvements in skin thickness, elasticity, and wrinkle depth in aged skin (Leyden et al., Abdulghani et al., Finkley et al. — classical GHK-Cu facial cream studies cited across the copper-peptide cosmetic literature). These are adduced as supporting evidence for Pal-GHK on the mechanistic premise that the active signaling moiety (GHK) is the same and that Pal-GHK generates GHK-Cu-like activity in situ.
• In vitro fibroblast studies (multiple) — Cell-culture studies using Pal-GHK or GHK at fibroblast-relevant concentrations (0.1–10 μM) demonstrate increases in procollagen synthesis, fibronectin deposition, and glycosaminoglycan secretion. Reported effect magnitudes range from modest (15–30%) to substantial (2-fold or greater) depending on experimental conditions, control comparator, and end-point timing.
• Pal-GHK + cosmetic-excipient formulation studies — Published in vivo cosmetic-science literature (e.g., Vaillant-Ciszewicz and others in the instrumental-evaluation literature) has evaluated facial/eye-cream formulations containing palmitoyl peptides alongside Silybum marianum seed oil, vitamin E, and other functional ingredients, reporting improvements in skin wrinkles, elasticity, and dermal density over 4-week application windows. These studies evaluate multi-ingredient cosmetic formulations; the isolated Pal-GHK contribution is not cleanly attributable.
• Negative / null findings — The published negative-finding record for Pal-GHK specifically is thin because most negative trials of matrikine cosmetic ingredients do not reach peer-reviewed publication; the absence of negative reports does not confirm efficacy. Independent meta-analyses of cosmetic peptide efficacy have repeatedly flagged the "manufacturer-sponsorship-plus-missing-independent-replication" pattern across the matrikine class.

Human Data

Human data for Pal-GHK is predominantly formulation-level (Matrixyl 3000-containing products) rather than isolated peptide-monotherapy. The following is a representative summary of the human-subject research base, organized from most directly relevant to mechanistic-support:

• Robinson 2005 — Pal-KTTKS, photoaged facial skin (Int J Cosmet Sci 2005; 27(3):155-160) — 12-week double-blind split-face placebo-controlled study in 93 Caucasian women aged 35–55. Pal-KTTKS at 3 ppm in a moisturizer cream vs moisturizer-only control. Statistically significant improvements in wrinkles/fine lines vs placebo by quantitative image analysis and expert-grader assessment. This trial established the palmitoylated-matrikine proof-of-concept on which Pal-GHK formulations are marketed; the active peptide is Pal-KTTKS (not Pal-GHK).
• Osborne 2005 — Pal-KTTKS moisturizer (J Am Acad Dermatol 2005) — 8-week double-blind split-face randomized study in women aged 35–65. Pal-KTTKS-containing moisturizer vs placebo moisturizer. Reported improvements in bumpy texture, fine lines, and wrinkle appearance. Same family of molecule as Pal-GHK, same signaling class (matrikine), different peptide.
• Mas-Chamberlin / Lintner 2002 — palmitoyl-peptide antiwrinkle study (Ann Dermatol Venereol) — 4-month clinical double-blind study vs excipient, presented at the 20th World Congress of Dermatology, Paris 2002. Cited extensively in Sederma's technical dossiers as part of the early clinical base for the Matrixyl matrikine family.
• Sederma Matrixyl 3000 (Pal-GHK + Pal-GQPR) internal study — Reported in Sederma's own dossier: 49 women aged 39–74 applied a cream with 3% Matrixyl 3000 morning and night for 2 months to the crow's-feet area on one side of the face, and a placebo cream (24 women) or a Matrixyl cream (25 women) to the other side; wrinkles were measured on silicone skin replicas on days 0 and 56. Against the placebo side, the area of deep wrinkles fell 39.4% (placebo +4.3%), wrinkle density 32.6% (placebo −9.6%), and the depth and volume of the main wrinkle 19.9% and 23.3% (placebo −3.2% and −8.7%); against Matrixyl, no difference was statistically significant (Sederma's Matrixyl 3000 dossier). Not published as a peer-reviewed clinical trial.
• Instrumental-evaluation facial-cream studies (palmitoyl-peptide blends) — Published cosmetic-science literature has evaluated facial and eye-cream formulations containing palmitoyl peptides alongside botanical extracts (Silybum marianum), vitamin E, and other cosmetic actives, reporting improvements in wrinkles, elasticity, and dermal density over 4-week application periods using instrumental skin bioengineering techniques (Cutometer, Reviscometer, Dermascan, corneometer).
• Related — Palmitoyl Pentapeptide-4 (Matrixyl / Pal-KTTKS) ongoing clinical literature — Multiple subsequent in-vivo cosmetic trials across 2005–2020 have used Pal-KTTKS as a comparator or co-active; these inform the topical-matrikine literature but do not add direct Pal-GHK human data.
• Related — GHK-Cu cream facial studies — Classical GHK-Cu cosmetic trials (Leyden, Abdulghani, Finkley — widely cited across the copper-peptide literature) report improvements in skin thickness, elasticity, and wrinkles over 12-week application windows. These are GHK-Cu — not Pal-GHK — and are cited as mechanistic support rather than direct Pal-GHK evidence.
• No FDA-monitored clinical-trial database entry for Pal-GHK — ClinicalTrials.gov does not contain a registered interventional trial of Pal-GHK monotherapy as of April 2026. As a cosmetic ingredient rather than a drug, Pal-GHK has not been evaluated through the investigational new drug (IND) / clinical-trial pathway.
• Honest assessment — The human evidence base for Pal-GHK specifically is limited. The matrikine-cosmetic class has better-quality data, but most of that data is for Pal-KTTKS (the original Matrixyl) rather than Pal-GHK. The Matrixyl 3000 data cannot isolate the Pal-GHK component. The mechanistic case for Pal-GHK as a topical GHK-Cu-precursor is scientifically reasonable; the clinical-efficacy case is extrapolated and supported primarily by manufacturer-generated data.

Reconstitution & Storage

Pal-GHK is not a lyophilized injectable peptide and does not require bacteriostatic-water reconstitution. Matrixyl 3000 is supplied as a ready-made, preservative-free solution of glycerin, butylene glycol, water, carbomer and polysorbate-20 holding 100 ppm Pal-GHK and 50 ppm Pal-GQPR (Sederma's Matrixyl 3000 dossier); Pal-GHK on its own is a white powder (Johnson et al., 2018).

• Handling and storage — One seller's formulation guide for a blend of the same two peptides lists adding it at the end of emulsion making, at cool-down below 40°C, and long-term storage at 4°C (read October 2026).

→ Calculator — vial-to-syringe math

Side Effects & Risks

The Cosmetic Ingredient Review's expert panel concluded in 2014 that palmitoyl tripeptide-1 is safe in cosmetics at the concentrations used, typically under 10 ppm, citing the low concentrations and negative irritation, sensitization and gene-toxicity tests (Johnson et al., 2018). Those tests were short-term and run on ingredient mixtures holding 100 or 1,000 ppm Pal-GHK, and CIR found no long-term, reproductive or cancer study of it (Johnson et al., 2018).

• Irritation / contact dermatitis — In a 48-hour patch test of an ingredient mixture with 1,000 ppm Pal-GHK, none of 10 adults had irritation; in a repeated-patch test of the same mixture in 52 people, reactions were faint to moderate and were judged not clinically significant (Johnson et al., 2018). A 100 ppm mixture was classed as non-irritating to rabbit and guinea-pig skin (Johnson et al., 2018).
• Allergic contact dermatitis — No case report of allergy to Pal-GHK appears in PubMed (searched October 2026). The 52-person repeated-patch test above found no clinically significant sensitization, and a 100 ppm mixture did not sensitize guinea pigs (Johnson et al., 2018).
• Photosensitivity — Not studied: CIR's safety review lists no phototoxicity or photoallergy test of Pal-GHK (Johnson et al., 2018).
• Pregnancy and lactation — No data: CIR found no reproductive or developmental toxicity study (Johnson et al., 2018), and it has not been tested in pregnancy or breastfeeding. Use in pregnancy or breastfeeding is a question for a licensed obstetric or dermatology provider.
• Pediatric use — No study has tested Pal-GHK in children; its efficacy tests were in adult women (Sederma's Matrixyl 3000 dossier; Johnson et al., 2018).
• Copper-overload theoretical concern — Pal-GHK carries no copper (CosIng), but its GHK part binds copper (Pickart, 2008), so it might pick up copper in the skin. This is theoretical: no study has measured it, or looked at people with copper disorders such as Wilson or Menkes disease.
• Systemic effects — Not studied for Pal-GHK. Plain GHK injected into the veins of rats was rapidly broken down and cleared within minutes, and GHK is unstable in human plasma (Johnson et al., 2018).
• Long-term safety — No long-term study has been published (Johnson et al., 2018). The CIR panel's safe-as-used conclusion rests on short-term tests and the low concentrations in products (Johnson et al., 2018).

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for Pal-GHK, and none of its published tests took blood. Sederma's tests measured wrinkles on silicone replicas of the skin, skin elasticity and tone (Sederma's Matrixyl 3000 dossier), and skin thickness by ultrasound (Lintner & Peschard, 2000; Johnson et al., 2018).

Commonly Stacked With

Pal-GHK is sold mainly as part of Matrixyl 3000, Sederma's mix of it with Pal-GQPR (Sederma's Matrixyl 3000 dossier), or blends like it. To see what else it is sold with, Kalios checked 50 product ingredient lists that include it (the first 50 an online ingredient database shows, October 2026; a few are versions of one product): 42 also list Pal-GQPR. No published study has compared Pal-GHK with and without any of the partners below, except Sederma's tests of the Matrixyl 3000 mix.

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

Palmitoyl-tripeptide siblings and GHK-family actives:

Next Steps

References

1. Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science. 2005;27(3):155-160. doi:10.1111/j.1467-2494.2005.00261.x. PMID: 18492182. (Foundational 12-week double-blind split-face RCT in 93 women aged 35–55; established the topical palmitoyl-matrikine proof-of-concept on which the Matrixyl / Matrixyl 3000 family — including Pal-GHK — is marketed.)
2. Pickart L. The human tri-peptide GHK and tissue remodeling. Journal of Biomaterials Science, Polymer Edition. 2008;19(8):969-988. doi:10.1163/156856208784909435. PMID: 18644225. (Foundational review of the parent tripeptide GHK, its tissue-remodeling biology, and the copper-coordination mechanism underlying GHK-Cu signaling — directly relevant to Pal-GHK's proposed in situ GHK-Cu formation.)
3. Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. BioMed Research International. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26236730; PMC4508379. (Comprehensive review of GHK's multi-pathway skin-regenerative signaling — collagen, fibronectin, decorin, GAGs, anti-inflammatory, antioxidant effects — all of which are extrapolated to Pal-GHK on the shared head-group argument.)
4. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520; PMC6073405. (2018 gene-expression-based review using Broad Institute Connectivity Map data; demonstrates GHK-Cu modulation of thousands of genes across ECM synthesis, DNA repair, apoptosis, and antioxidant pathways.)
5. Pickart L, Vasquez-Soltero JM, Margolina A. The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health. Oxidative Medicine and Cellular Longevity. 2012;2012:324832. PMID: 22666519. (Mechanistic foundation for antioxidant / oxidative-stress modulation; extrapolated to Pal-GHK via shared GHK head group.)
6. Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters. 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID: 3169264. (The foundational in vitro demonstration of GHK-Cu-driven fibroblast collagen synthesis — the mechanism that Pal-GHK is hypothesized to engage in situ after palmitoyl-delivery to the dermis.)
7. Ricard-Blum S, Salza R. Matricryptins and matrikines: biologically active fragments of the extracellular matrix. Experimental Dermatology. 2014;23(7):457-463. doi:10.1111/exd.12435. PMID: 24815015. (Modern framework paper defining the matrikine / matricryptin class to which GHK and Pal-GHK belong.)
8. Maquart FX, Pasco S, Ramont L, Hornebeck W, Monboisse JC. An introduction to matrikines: extracellular matrix-derived peptides which regulate cell activity. Implication in tumor invasion. Critical Reviews in Oncology/Hematology. 2004;49(3):199-202. doi:10.1016/j.critrevonc.2003.06.007. (Seminal review introducing the matrikine concept; the theoretical foundation for palmitoyl-matrikine cosmetic actives.)
9. Osborne R, Robinson LR, Mullins L, Raleigh P. Use of a facial moisturizer containing palmitoyl pentapeptide improves the appearance of aging skin. Journal of the American Academy of Dermatology. 2005;52(3 Suppl):P43. (Supporting 8-week split-face human data on the palmitoyl-pentapeptide Matrixyl, the direct precursor to Matrixyl 3000 / Pal-GHK.)
10. Mas-Chamberlin C, Lintner K, Basset L, Adhoute H, Revuz J. Relevance of antiwrinkle treatment of a peptide: 4 months clinical double blind study vs excipient. Annales de Dermatologie et de Vénéréologie. 2002;129(1S):456. Proceedings, 20th World Congress of Dermatology, Paris. (Early clinical data on the Sederma palmitoyl-peptide program that seeded the Matrixyl and Matrixyl 3000 actives.)
11. Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. International Journal of Cosmetic Science. 2000;22(3):207-218. doi:10.1046/j.1467-2494.2000.00010.x. (Sederma researcher review of the palmitoyl-peptide lipidation-for-permeation strategy that underlies Pal-GHK delivery pharmacology.)
12. Pickart L, Vasquez-Soltero JM, Margolina A. The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline. Brain Sciences. 2017;7(2):20. doi:10.3390/brainsci7020020. PMID: 28212278. (Extension of GHK transcriptomic effects; relevant to Pal-GHK only indirectly via shared head group.)
13. Gruchlik A, Jurzak M, Chodurek E, Dzierzewicz Z. Effect of Gly-Gly-His, Gly-His-Lys and their copper complexes on TNF-alpha-dependent IL-6 secretion in normal human dermal fibroblasts. Acta Poloniae Pharmaceutica. 2012;69(6):1303-1306. PMID: 23285694. (Direct anti-inflammatory cytokine data for the GHK head group and its copper complex in dermal fibroblasts.)
14. Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029. (Contemporary MDPI Cosmetics review of copper-peptide skin biology applicable to the Pal-GHK-in-situ-GHK-Cu formation hypothesis.)
15. Finkley MB, Appa Y, Bhandarkar S. Copper peptide and skin. Cosmeceuticals and Active Cosmetics: Drugs vs. Cosmetics. Marcel Dekker, New York; 2005:549–563. (Classical cosmetic-dermatology chapter summarizing GHK-Cu-containing facial cream clinical data — the cream data most often cited as mechanistic support for Pal-GHK cosmetic efficacy.)
16. Abdulghani AA, Sherr A, Shirin S, Solodkina G, Tapia EM, Wolf B, Gottlieb AB. Effects of topical creams containing vitamin C, a copper-binding peptide cream, and melatonin compared with tretinoin on the ultrastructure of normal skin: a pilot clinical, histologic, and ultrastructural study. Disease Management & Clinical Outcomes. 1998;1(4):136-141. (Copper-peptide cream ultrastructural skin-effect data used throughout the copper-peptide cosmetic literature as supporting evidence.)
17. Leyden JJ, Stephens T, Finkey MB, Appa Y, Barkovic S. Skin breakdown in adult diapers. Poster presentation, 60th Annual Meeting American Academy of Dermatology; February 22–27, 2002; New Orleans, LA. (Copper-peptide facial cream clinical data, part of the Neova / ProCyte GHK-Cu development package.)
18. Sederma (Croda International). Matrixyl 3000 technical dossier and product information sheets. Sederma, Le Perray-en-Yvelines, France. 2003–2024. (Manufacturer's technical documentation for the Pal-GHK + Pal-GQPR combination active — the primary source for recommended use levels, stability data, and unpublished in-house clinical trials on wrinkle volume / density / depth reductions at 3% Matrixyl 3000 over 56-day protocols.)
19. European Commission. CosIng — Cosmetic Ingredient Database entry: Palmitoyl Tripeptide-1. (Official EU regulatory listing confirming cosmetic ingredient status in the EU single market.)
20. U.S. Food and Drug Administration. Federal Food, Drug, and Cosmetic Act — Cosmetic Product Ingredient Regulatory Framework. (Regulatory context for topical cosmetic peptides including Palmitoyl Tripeptide-1; FDA does not pre-approve cosmetic ingredients but monitors adulteration and misbranding.)
21. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
22. Johnson W Jr, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Gill LJ, Heldreth B. Safety Assessment of Tripeptide-1, Hexapeptide-12, Their Metal Salts and Fatty Acyl Derivatives, and Palmitoyl Tetrapeptide-7 as Used in Cosmetics. International Journal of Toxicology. 2018;37(3 suppl):90S-102S. doi:10.1177/1091581818807863. (Cosmetic Ingredient Review final report, released June 30, 2014: cir-safety.org/sites/default/files/tripep062014final.pdf, read October 4, 2026. Use concentrations of palmitoyl tripeptide-1 reported in the 2013–2014 industry survey, the safety tests of Pal-GHK ingredient mixtures, summaries of the maker's Pal-GHK tests, and the Panel's conclusion that it is safe as used.)

Related Research

• AHK-CuCopper Tripeptide (Hair)
• ArgirelineSNAP-25 Mimetic
• Decapeptide-12Tyrosinase Inhibitor
• MatrixylCollagen Signal Peptide
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.